

The pan-Canadian Oncology Drug Review

November 1 2010

Dear Sir/Madam,

As follow-up to my letter of October 18, 2010, I am writing to you today to provide further information about an upcoming pan-Canadian Oncology Drug Review (pCODR) information session.

A newly established evidence-based cancer drug review process, the pCODR is designed to assess the clinical evidence and cost-effectiveness of new cancer drugs, and to use this information to make recommendations to the provinces and territories in guiding their drug funding decisions. The implementation of the pCODR is well underway and the anticipated rollout will begin in early 2011.

As I noted in my first correspondence, our partners in the pCODR collaboration have been working to shape the submission and review process. Many of you provided significant input through the interim JODR, and to further assist in the development of the pCODR and to hear about progress to date, **we are inviting you to an information and input session for pharmaceutical industry representatives on November 25, 2010** at the Hilton Garden Inn Toronto Airport West/Mississauga, 1870 Matheson Boulevard East, Mississauga, from **9:30am to noon**, in meeting room McCallion B.

We have been working constructively with the Industry Oncology Working Group (IOWG) to identify early operational issues. The November 25th session will provide an opportunity for the broader pharmaceutical industry to participate and provide input into a) ways in which the pCODR process can reflect its guiding principles of fair and transparent governance, and cross-jurisdictional collaboration and b) the draft pCODR process. We value the contributions of the pharmaceutical industry in supporting work to shape the pCODR process and we hope you will be able to join us for this session.

Moving Forward

The role of the pCODR Expert Review Committee (pERC) is to take the clinical and economic information relating to the cancer drug under review, and to formulate a funding recommendation for the provinces and territories. Once the nomination and selection process for that committee has been finalized, which is likely early December 2010, we will be in touch to seek your suggestions on nominations for the pERC Chair.

Please confirm your attendance at the information and input session via e-mail: rsvp@pcodr.ca Once we have your RSVP, we will send the agenda.

We look forward to our continued work together,

Sincerely,



Mona Sabharwal
Executive Director
pan-Canadian Oncology Drug Review
1 University Avenue, suite 300
Toronto, ON M5J2P1
p: 416-619-5743
f: 416-915-9224
e: mona.sabharwal@pcodr.ca

cc: pCODR Steering Committee